These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T, Tachibana S, Shibata T. PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887 [Abstract] [Full Text] [Related]
3. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys. Kostenuik PJ, Smith SY, Samadfam R, Jolette J, Zhou L, Ominsky MS. J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992 [Abstract] [Full Text] [Related]
4. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685 [Abstract] [Full Text] [Related]
8. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M. Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112 [Abstract] [Full Text] [Related]
11. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group. J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495 [Abstract] [Full Text] [Related]
16. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Osteoporos Int; 2006 Mar; 17(6):942-9. PubMed ID: 16550299 [Abstract] [Full Text] [Related]
17. The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. Ramchand SK, Tsai JN, Lee H, Sassana-Khadka G, Jordan M, Ryan S, Leder BZ. Osteoporos Int; 2024 Feb; 35(2):255-263. PubMed ID: 37798320 [Abstract] [Full Text] [Related]
18. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. Iwamoto N, Okamoto M, Tsuji S, Endo Y, Takatani A, Shimizu T, Umeda M, Fukui S, Sumiyoshi R, Igawa T, Koga T, Kawashiri SY, Aramaki T, Ichinose K, Tamai M, Nakamura H, Origuchi T, Eguchi K, Ueki Y, Kawakami A. J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273 [Abstract] [Full Text] [Related]
20. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA. Osteoporos Int; 2006 May; 17(5):716-23. PubMed ID: 16463007 [Abstract] [Full Text] [Related] Page: [Next] [New Search]